Introduction: Metformin and glucagon-like peptide-1 (GLP-1) agonists are widely used
| INTRODUCTION
Gastrointestinal tract (GIT) microbiome dysbiosis is associated with increased severity of type two diabetes mellitus (T2DM), yet interactions between diabetes medicines and bacterial communities are just being investigated. While metformin is the most widely prescribed drug for T2DM, its mechanism of action remains unclear.
Mitochondrial function and AMPK activity in liver and skeletal muscle as well as facilitation of active glucagon-like peptide-1 (GLP-1) secretion have been suggested as potential mechanisms 1 . In contrast to oral dosing, intravenously administered metformin does not improve glucose metabolism, suggesting that the gastrointestinal tract may be the principal site of drug action. 2 Recent studies suggest that metformin treatment does alter the human GIT microbiome and could be an important pharmacological effect of this drug.
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Another pharmaceutical approach to treat T2DM is to enhance GLP-1 function, either by the administration of GLP-1 peptide mimetics (ie liraglutide) or suppressing its degradation by dipeptidyl peptidase-4 (DPP-4) (ie saxagliptin, sitagliptin). Short-chain fatty acids (SCFAs) produced through bacterial metabolism also induce GLP-1 expression via binding with the G-coupled protein receptor, FFAR2 (formerly GPR43). Studies in mice show that liraglutide but not saxagliptin alters the gut microbiome suggesting a relationship between GIT microbes and GLP-1 agonism. 6, 7 In patients with T2DM taking liraglutide, sitagliptin or placebo, only liraglutide increased serum levels of deoxycholic acid, a secondary bile acid produced by bacterial metabolism. Here, we describe the first comparative analysis of microbiome changes in a T2DM human cohort taking either metformin or liraglutide. 9 Originally, these data were collected in a clinical study designed to test the efficacy and safety of a novel combination of four nutritional agents (GSK2890457) intended to be used as a metabolic potentiate in combination with existing treatments for obesity and T2DM
(ClinicalTrials.gov NCT01725126). While GSK2890457 showed significant weight loss and reduction in glucose levels in diet-induced obese mouse models, these preclinical effects did not translate into human.
However, during this clinical trial, we found specific evidence for the novel effects of liraglutide and metformin on the human microbiome, which we present herein.
| MATERIALS AND METHODS

| Study design
Detailed methods are provided in Appendix S1. Briefly, the study population, clinical trial design and ethics statement (SMP116623; www.clinicaltrials.gov NCT01725126) were previously described. Associates Institutional Review Board, and a copy is available as Appendix S1 in Hodge et al. 9 All subjects provided written informed consent before enrolment.
T2DM subjects (n = 37) who were stable on metformin were randomized into two study arms, Part B and Part C ( Figure 1A ). Part A was comprised of only health volunteers. Microbiome analysis was not performed on these subjects; therefore, data pertaining to this subgroup are not presented here. After a single-week familiarization period, Part B subjects (n = 19) were switched from oral metformin to subcutaneous once daily injections of liraglutide. Measurements and samples were taken after the completion of a twelve-week stabilization period. Part C subjects (n = 18) remained on metformin for the duration of the study with a 4-week stabilization period.
The metformin-liraglutide substitution design was used because a prestudy feasibility assessment determined that it was impossible to recruit sufficient subjects with liraglutide as their primary T2DM medication. 9 After the stabilization period, subjects were further randomized to receive either placebo or GSK2890457, a mixture of four nutritional ingredients: oligofructosaccharide (OFS), apple pectin, black-current extract and oleic acid in a ratio of 5:5:2:3.
Each ingredient is a generally regarded as safe (GRAS) substance and present in normal diet. Subjects were fed standardized meals on pharmacodynamic profiling days. Age, sex, race, BMI, weight change and years duration of T2DM were recorded along with measured glucose levels.
Considerable effort was made to standardize medications and diet as to minimize potential inter-subject variation in pharmacodynamic and microbiome measurements. The study protocol has an extensive list of exclusion criteria based on co-morbidity diseases and concom- If an enrolled subject presented with an active infection 2 days prior to stool sampling, the visit was rescheduled once the signs/symptoms
were absent for at least 5 days and/or antibiotic therapy ceased for at least 4 weeks.
At the beginning of the treatment period, all subjects were given a Block Brief Food Frequency Questionnaire (a validated questionnaire obtained from and analysed by Nutrition Quest Inc., Berkeley, CA, USA). Mann-Whitney-Wilcoxon FDR P-values are nonsignificant for all diet variables in comparisons between subjects on liraglutide and metformin or subjects treated with either placebo or GSK2890457 (Appendix S2). Throughout the study, subjects were on the diet recommended by their primary care physician. Subjects were also made to visit the clinical centre during weeks 7, 14 and 28 for evaluation and monitoring compliance. Noncompliance with the medication, self-monitoring and/or expected lifestyle regimens lead to subject exclusion from the study.
| Microbiome sampling and analysis
Stool samples (n = 74) were taken just prior to commencement of placebo or GSK2890457 dosing (baseline or Day 0) and at the end of the 6-week trial period (Day 42). Prior to the two stool collections, subjects were placed on a standardized diet beginning with dinner at Day -2 (2 days before stool sampling) and breakfast, lunch and dinner during Day -1 (1 day before stool sampling).
Stool samples were collected with a sterile spoon, transferred into a prelabelled tube containing 8 mL of Stool DNA Stabilizer, mixed 
| Bioinformatics and statistical analysis
As previously described by us, 4 quality filtering and analyses of multiplexed DNA sequencing reads were performed using QIIME 1.8. 10 The remaining reads were subject to a 97% identity cut-off open-reference OTU picking using the UCLUST method. 11 The OTU table was rarefied to a depth of 51 967 sequences. Beta diversity was estimated using the weighted UniFrac distance and visualized by principal coordinate analysis (PCoA). Analysis of similarities (ANOSIM) was used to assess the significance of separation between the tested groups of samples. Differentially represented bacterial genera for all comparisons were identified using edgeR in R bioconductor. 12 Correlation between bacterial genera and patient demographic variables were calculated using Spearman Rank Correlation. Sequence data are available from the National Center for Biotechnology Information Sequence Read Archive (SRP107313).
| RESULTS
High-quality 16S rRNA gene sequencing data were obtained for all 74 stool samples. A total of 12 531 456 DNA sequencing reads were left after demultiplexing and quality control filtering. A rarefaction depth of 51 967 reads per sample was selected, and 11 800 OTUs were identified across 74 samples. the family Christensenellaceae showed a significant increase in liraglutide relative to metformin subjects and the genera Dorea and Sutterella increased significantly in metformin subjects (adj. P < .05, Figure 1D ).
At Day 42, when controlling for GSK2890457 and placebo treatments in the statistical model, a significant increase in Akkermansia and a significant decrease in Sutterella were observed in liraglutide relative to metformin subjects (adj. P < .05, Figure 1D ). No significant differences in any bacterial genera were observed in GSK2890457 relative to placebo subjects. The Akkermansia difference remained significant in liraglutide compared with metformin at Day 42, in patient subgroups with GSK2890457 or placebo, respectively (adj. P < .05).
To assess the stability of microbiome over time, we looked for any significant changes in bacterial genera between baseline and Day 42
within their respective liraglutide and metformin groups. We found that bacterial compositions were highly consistent between the time points. No significant changes in any bacterial genera were observed among liraglutide or metformin group, whether co-administered with GSK2890457 or placebo. Likewise, no significant changes in any bacterial genera were observed among GSK2890457 or placebo group, irrespective of the concurrent liraglutide or metformin treatment. This is consistent with the lack of overall clinical response to GSK2890457 treatment. 9 No statistically significant correlations were found between bacterial phyla or genera abundances and patient epidemiological variables (gender, race, age, body mass index and weight change). However, baseline fasting 24-hour glucose AUC levels were significantly positively correlated with the baseline relative abundance of Methanobrevibacter (Spearman's rho = 0.590; adj. P = .009, Figure S3A ). Bacteroides and Akkermansia were significantly associated with patient duration of diabetes (adj P < .05, Figure S3B ). Specifically, there was a significantly higher abundance of Akkermansia in patients with short and medium durations than those with long duration of diabetes.
| DISCUSSION
Our study shows that metformin and liraglutide treatments are associated with distinct GIT microbiome communities in T2DM human subjects. In a previous study, we found significant differences in bacterial composition, serum bile acid levels and GLP-1 associated with temporary metformin withdrawal in T2DM subjects. 4 In a crosssectional study, de la Cuesta-Zuluaga et al. Active GLP-1 likely plays a broad role in supporting gut homoeostasis as prophylactic administration of liraglutide has been shown to be protective in a T cell-driven adoptive transfer colitis mouse model.
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Our study suggests that GLP-1 agonism, maintenance of gut homoeostasis and Akkermansia species occurrence are inter-related factors for T2DM aetiology.
Our study has several caveats. First, the microbiome composition of patients at the onset of metformin-liraglutide substitution is unknown, which could be important to further attribute the microbiota differences in our cross-sectional comparison to the effect of liraglutide or metformin, or both. Ideally, one would also need to sample the microbiota in treatment-naïve subjects to more precisely understand the effects of liraglutide and metformin treatments. Second, the 16S rRNA sequencing has limitations in understanding the species/strain level diversity and functional capability of the gut microbiota. Further studies with shotgun metagenomic profiling are necessary to investigate biomarkers of improved gut barrier function and hyperglycaemic control.
Our work supports a growing body of evidence that metformin and GLP-1 agonists modulate the gut microbiome. Further studies to better understand the role of GIT pharmacology in the mechanisms of action of these drugs will assist in the development of future T2DM therapies.
